capital

medicine

Shore Capital Partners Announces Founding of Southern Sports Medicine Partners

Strategic Partnership with Jaffe Sports Medicine Includes Four Locations in West Florida

Shore Capital Partners (“Shore”), a private equity firm, is pleased to announce it has founded Southern Sports Medicine Partners (“SSMP”), through the completion of a strategic partnership with Jaffe Sports Medicine (“JSM”). SSMP provides interventional pain management practices with administrative support, so physicians can focus on delivering the highest quality of patient care.

JSM, led by founder Dr. Peter Jaffe, provides patient-centric care at four locations in the Naples, FL area. Mike Cooper, a founding partner of Shore, commented, “We are thrilled to partner with Dr. Jaffe. He is one of the most respected and well-known physicians in West Florida. Having built a world-class practice, Dr. Jaffe shares our vision to deliver clinical excellence at greater scale.”

Dr. Jaffe said, “I partnered with Shore for their track record of transformational growth in healthcare and a shared belief in what it will take to be the leading interventional pain management platform in the Southeast. As healthcare continues to become more retail and consumer-oriented, the time is ideal to embrace growth, patient experience, and best in class programs and options for physicians in all stages of their careers. Southern Sports Medicine Partners is off to a great start and I have high aspirations for what we can achieve.”

SSMP will grow its platform across the region by investing in people and processes to support the operations, finance, accounting, marketing, human resources, and IT functions at affiliated practices, thereby allowing physicians to focus on clinical excellence and serving their communities. SSMP will pursue affiliations with independent interventional pain management practices to build a network of top clinicians in a physician-led culture.

“We are building a leader of scale in pain management and sports medicine, starting with Dr. Jaffe and his team,” said Mr. Cooper. “We are well-positioned to support the continued transition to consumer-directed healthcare, while maintaining the physician’s role and clinical expertise as the most critical aspect of treatment. Additionally, Shore has helped to bring together an exceptional board of directors consisting of industry thought leaders and physicians alike to guide our strategy and growth plan.”

SSMP represents the third platform investment out of Shore Capital Partners Fund III, L.P., a $293 million investment vehicle raised in April 2019.

To learn more about Jaffe Sports Medicine, please visit www.jaffesportsmedicine.com.

About Shore Capital

Shore Capital Partners is a Chicago-based private equity firm focused on microcap Healthcare and Food and Beverage investments. Shore supports management partners with capital, business development expertise, and industry knowledge to accelerate growth, fund acquisitions, and generate value to shareholders. Shore targets investments in proven, successful private companies with superior management teams, stable cash flow, and significant growth potential, including organic and growth through industry consolidation. Shore has $1.1 billion of equity capital under management through various investment vehicles. For more information on Shore, please visit www.shorecp.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005029/en/

Contacts

Adam Werder
Shore Capital
(312) 348-7580
https://www.linkedin.com/company/shore-capital-partners/

Source Article

Read More
health

Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel

SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. Dr. Hasan Jafri, Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.”

Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus
Date: Wednesday, October 28, 2020
Time: 10:30AM-11:50AM ET

Dr. Jafri will present a summary of the Company’s recently published preclinical data of its COVID-19 inhaled mAb (AR-711). He will address the preclinical performance of AR-711, the advantages of direct lung delivery using nebulized aerosols, and the COVID-19 clinical program.

About AR-711

AR-711 is a fully human immunoglobulin 1, or IgG1, monoclonal antibody discovered from screening the antibody secreting B-cells of convalescent COVID-19 patients. AR-711 exhibits high affinity for SARS-CoV-2 spike protein, approximately 10-fold or higher than mAb candidates currently in late stage clinical testing. AR-711 was previously shown to be effective in prophylactic as well as therapeutic treatment modes in a SARS-CoV-2 viral challenge study. AR-711 is currently being developed as an inhaled, self-administered treatment for non-hospitalized patients suffering from mild to moderate COVID-19. AR-711 is also one the two mAbs in the company’s AR-701 mAb cocktail, which is a separate program being developed as an intravenous treatment of moderate to severe, hospitalized COVID-19 patients.

About Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary ʎPEXTM and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor’s immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality.

The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. The Company’s pipeline is highlighted below:

Aridis’ Pipeline

AR-301 (VAP). AR-301 is a fully human IgG1 mAb currently in Phase 3 clinical development targeting gram-positive 

Read More
health

India’s capital chokes on ‘severe’ smog as farm fires soar

New Delhi was blanketed in noxious haze Friday as air pollution levels in parts of the city soared to “severe” levels, hours after US President Donald Trump described the air in the vast nation as “filthy”.

Smoke from agricultural burning, vehicle fumes and industrial emissions — combined with cooler temperatures and slow-moving winds that trap pollutants over the city — turns air in the Indian capital into a toxic soup every winter.

The air quality index at Delhi’s 36 pollution monitoring sites — which monitors tiny PM2.5 and PM10 particles that get into the bloodstream and vital organs — was between 282 and 446, pushing levels into the “severe” category, the Central Pollution Control Board said.

The “good” category is between 0-50, the government’s environmental watchdog added.

A “significant increase in stubble fire count” to 1,213 in Haryana and Punjab states was the highest of this season and made up 17 percent of Delhi’s PM2.5 levels, the state-run System of Air Quality Weather Forecasting and Research added Friday.

“Further deterioration of (air quality) is expected for the two days,” SAFAR said.

This season’s burning started earlier because of advanced sowing and harvesting by farmers amid fears of labour shortages during the coronavirus pandemic, officials said.

The worsening conditions came as Trump complained that action on climate change was unfair to the US.

“Look at China, how filthy it is. Look at Russia, look at India — it’s filthy. The air is filthy,” Trump said at his presidential debate with Democratic rival Joe Biden.

Scientists warned this year’s pollution season would make Delhi’s 20 million residents more vulnerable to the coronavirus.

“Air pollution increases the risk of noncommunicable diseases — the same underlying conditions that make people more likely to experience severe illness or death from Covid-19,” epidemiologist Sumi Mehta from global non-profit Vital Strategies told AFP.

Healthcare systems, stretched by the pandemic, could be further stressed by more hospitalisations from pollution-related illnesses, researchers added.

“There are serious worries that during winter when higher air pollution levels in any case worsens respiratory illness and increases hospitalisation, the vulnerability to Covid-19 may be further enhanced,” Anumita Roy Chowdhury of the Delhi-based Centre for Science and Environment told AFP.

The chief medical officer of Gurugram city near New Delhi, Virender Yadav, told The Times of India Thursday some recovering Covid-19 patients were experiencing a reoccurence of respiratory conditions triggered by the heightened air pollution.

grk-ja/je

Source Article

Read More